Shannon Klinger - Novartis Executive
| NVSN Stock | MXN 1,540 0.00 0.00% |
Executive
Ms. Shannon Thyme Klinger was Group General Counsel, Member of the Executive Committee of Novartis Inc. since June 1, 2018. She was Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee at the Company from April 1, 2018. Before that, she was Chief Ethics and Compliance Officer and Global Head of Litigation. She joined Novartis in 2011 as General Counsel, North America, for Sandoz in the United States and later became the Global Head of Legal and General Counsel for Sandoz International GmbH. Prior to Novartis, Ms. Klinger worked in the United States as a partner at Mayer Brown LLP from 2010 to 2011, senior vice president and general counsel for Solvay Pharmaceuticals Inc. from 2008 to 2010, and vice president of marketing compliance and associate counsel for Barr LaboratoriesDuramed Pharmaceuticals from 2005 to 2007. She was also a partner at Alston Bird LLP, where she focused on litigation and antitrust, pharmaceutical legal and regulatory matters since 2018.
| Age | 48 |
| Tenure | 6 years |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | EXECUTIVE Age | ||
| Jefrey Pott | AstraZeneca PLC | N/A | |
| Adrian Kemp | AstraZeneca PLC | N/A | |
| Jeffrey Pott | AstraZeneca PLC | N/A | |
| Thomas Larsen | AstraZeneca PLC | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Verena Briner, Non-Executive Independent Member of the Board | ||
| Karen Hale, Chief Officer | ||
| Chris Ilsley, President CEO | ||
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Richard Francis, Member of the Executive Committee and Division Head, Sandoz | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Pierre Landolt, Member of the Board of Directors | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Erwin Vanhaecke, Head Novartis Group Quality | ||
| Elizabeth Barrett, CEO, Novartis Oncology | ||
| Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Samir Shah, Global Head Investor Relations | ||
| David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals | ||
| Srikant Datar, Non-Executive Independent Director | ||
| MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Samir MD, Global Relations | ||
| Simon Moroney, Non-Executive Independent Director | ||
| Francesco Balestrieri, CEO of Sandoz, Member of the Executive Committee | ||
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
| Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Brian McNamara, Member of the Management Board, Division Head, Novartis OTC | ||
| Andrews C, Non-Executive Independent Director | ||
| Michele Galen, Head Communications | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
| Dimitri Azar, Non-Executive Independent Director | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
| Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland | ||
| Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Michael Ball, CEO of Alcon, Member of the Executive Committee | ||
| Jeffrey George, Member of the Executive Committee and Division Head, Sandoz | ||
| Patrice Bula, Non-Executive Independent Director | ||
| Peter Kornicker, Chief Compliance Officer | ||
| Andreas Planta, Non-Executive Independent Director | ||
| Joseph Jimenez, CEO, Member of the Executive Committee | ||
| Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Non-Executive Independent Director | ||
| George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility | ||
| Paul Arkel, Head of Corporate Strategy and External Affairs | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
| Felix Ehrat, General Counsel and General Counsel of Novartis International Ag | ||
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
| Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics | ||
| Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 4.12 T | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Institutions | 8.23 % | |||
| Price To Earning | 24.95 X | |||
| Price To Book | 2.82 X | |||
| Price To Sales | 74.58 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |